NGEN vs NKTX

NervGen Pharma Corp. vs Nkarta, Inc. — Valuation Comparison 2026

NGEN

Biotechnology
NervGen Pharma Corp.
Quality
3.1
out of 10
Value Trap
Price
$2.08
Last close
Models
6/13
Active
VS

NKTX

Biotechnology
Nkarta, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NGEN Fair ValueNGEN Upside NKTX Fair ValueNKTX Upside
Bayesian DCF Intrinsic $0.64 -69.5% $0.66 -80.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.09 -95.6% $2.32 -29.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NGEN vs NKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NGEN vs NKTX — Which Stock Is More Undervalued?

NKTX scores higher with a 4.6/10 quality rating vs NGEN's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NervGen Pharma Corp. (NGEN) and Nkarta, Inc. (NKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NGEN currently trades at $2.08 with a QOC of 3.1/10, while NKTX trades at $3.30 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).